Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid ...

A look inside the rise of "The Barbie Drug," an unregulated, understudied injection that promises bronzed skin—and a load of ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down after eight years at the helm, as the Danish pharmaceutical giant ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Science-Backed PhenQ Supplement Offers a Natural, Multi-Action Alternative to GLP-1 Drugs Like Ozempic-Empowering 2025 Weight ...

Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Kaddis said insurers are locked in a cat-and-mouse game with drugmakers as the insurance sector invests in biosimilars and ...